By using this site, you agree to the Privacy Statement.
Board of Directors and Governance
Biomarkers Consortium
Biomarkers Consortium Programs
Submit a Project Concept
About the Biomarkers Consortium
Join Biomarkers Consortium
Benefits of a Membership
GeneConvene Global Collaborative
About GeneConvene
GeneConvene's Work and Impact
Work with GeneConvene
Contact GeneConvene
Major Completed Programs
Annual Support
Biomedical Research Programs
Educational & Training Programs
Lectures Awards & Events
Patient Support Programs
Why Get Involved
National Institute on Aging (NIA)
To tackle the human health challenges that face the world today, the FNIH develops collaborations with top experts from government, industry, academia and the not-for-profit sector and provides a neutral environment where we can work productively toward a common goal.
The Moderate Alcohol and Cardiovascular Health Trial (MACH15)
The Moderate Alcohol and Cardiovascular Health Trial (MACH15) was a longitudinal, international clinical trial to determine the effects of moderate alcohol use on cardiovascular disease and diabetes.
Accelerating Medicines Partnership - Parkinson's Disease
In 2016, the AMP Executive Committee approved the planning of an AMP effort to confront the challenges presented by Parkinson's disease (PD). This complements current efforts in the areas of Alzheimer's disease, type 2 diabetes and the autoimmune disorders of rheumatoid arthritis and systemic lupus erythematosus (lupus). A critical component of this partnership is that all members have agreed to make the AMP Parkinson's disease (AMP PD) data and analyses publicly available to the broad biomedical community.
Plasticity and Mechanisms of Cognitive Remediation in Older Adults
Plasticity and Mechanisms of Cognitive Remediation in Older Adults supports a grant for a multicenter clinical research trial on remediating age-related cognitive decline through mindfulness-based stress reduction and exercise.
Accelerating Medicines Partnership - Alzheimer's Disease
The Accelerating Medicines Partnership Alzheimer's Disease Project (AMP-AD) is a precompetitive partnership among government, industry, and nonprofit organizations that focuses on discovering novel, clinically relevant therapeutic targets and on developing biomarkers to help validate existing therapeutic targets.
Osteoarthritis Initiative
The Osteoarthritis Initiative was a public-private collaboration to improve the efficiency of drug development and clinical trials for the treatment of osteoarthritis, which affects more than 30 million adults in the United States.
Biomarkers Consortium - Inflammatory Markers for Early Detection and Subtyping of Neurodegenerative and Mood Disorders
This project will aim to standardize and validate measurement methods for inflammatory markers associated with Alzheimer's Disease and/or Major Depressive Disorder to ultimately identify a unique biosignature of disease. The identified biosignature would greatly assist with medication development, patient diagnosing, and patient selection for clinical trials.
Biomarkers Consortium - Use of Targeted Multiplex Proteomic Strategies to Identify CSF-Based Biomarkers in Alzheimer's Disease
The AD Targeted Cerebrospinal Fluid (CSF) Proteomics Project, completed in Q2Y15, completed an initial validation of a multiplexed panel of known biomarkers, examined BACE levels and enzymatic activity, and set up the initial validation of a mass spectroscopy panel using AD cerebrospinal fluid samples from the Alzheimer's Disease Neuroimaging Initiative (ADNI).
Biomarkers Consortium - Sarcopenia as a Valid Biomarker for Identifying Individuals at Risk of Disability
Sarcopenia 2 seeks to establish evidence-based cut-points for muscle mass and strength and determine their predictive validity for clinically meaningful outcomes (such as mobility, fractures, hospitalization and death); evaluate relative strength as a discriminator for mobility limitation and incident disability; and explore the potential usefulness of sarcopenia as a clinical endpoint in randomized clinical trials.
Biomarkers Consortium - Establish Guidelines for Initial Diagnostic Criteria for "Sarcopenia with Clinically Important Weakness" and Associated Evidence for Treatment Benefit
The Sarcopenia 1 project launched in 2010 and aimed to establish the first evidence-based definition of sarcopenia (muscle weakness), which is still not recognized as a medical condition.
Biomarkers Consortium - Osteoarthritis Biomarkers Project
The Biomarkers Consortium - Osteoarthritis Biomarkers Project is a $3.4 million study aimed at determining which biomarkers have greater prognostic ability to measure early progression of structural and symptomatic changes in the joint over time and which are likely to predict treatment response better than the radiographic measurement of narrowing of joint space in knee OA patients. These new biomarkers are candidates for follow-on studies for evaluation and use in regulatory decision-making.
Lectures, Awards and Events (9) Apply Lectures, Awards and Events filter
Neurodegenerative Disorder (6) Apply Neurodegenerative Disorder filter
Aging (3) Apply Aging filter
Osteoporosis (3) Apply Osteoporosis filter
Musculoskeletal Disorders (2) Apply Musculoskeletal Disorders filter
Psychiatry (1) Apply Psychiatry filter
(-) Remove National Institute on Aging (NIA) filter National Institute on Aging (NIA)
Food and Drug Administration (31) Apply Food and Drug Administration filter
National Cancer Institute (NCI) (16) Apply National Cancer Institute (NCI) filter
National Institute of Allergy and Infectious Diseases (NIAID) (15) Apply National Institute of Allergy and Infectious Diseases (NIAID) filter
National Institute of Neurological Disorders and Stroke (NINDS) (8) Apply National Institute of Neurological Disorders and Stroke (NINDS) filter
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) (7) Apply National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) filter
National Institute of Mental Health (NIMH) (7) Apply National Institute of Mental Health (NIMH) filter
National Institutes of Health (NIH) (7) Apply National Institutes of Health (NIH) filter
National Heart, Lung, and Blood Institute (NHLBI) (6) Apply National Heart, Lung, and Blood Institute (NHLBI) filter
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (5) Apply National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) filter
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (3) Apply Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) filter
National Center for Advancing Translational Sciences (NCATS) (2) Apply National Center for Advancing Translational Sciences (NCATS) filter
National Institute on Alcohol Abuse and Alcoholism (NIAAA) (2) Apply National Institute on Alcohol Abuse and Alcoholism (NIAAA) filter
NIH Office of the Director (OD) (2) Apply NIH Office of the Director (OD) filter
Fogarty International Center (FIC) (1) Apply Fogarty International Center (FIC) filter
National Center for Complementary and Integrative Health (NCCIH) (1) Apply National Center for Complementary and Integrative Health (NCCIH) filter
National Eye Institute (NEI) (1) Apply National Eye Institute (NEI) filter
National Human Genome Research Institute (NHGRI) (1) Apply National Human Genome Research Institute (NHGRI) filter
National Institute on Deafness and Other Communication Disorders (NIDCD) (1) Apply National Institute on Deafness and Other Communication Disorders (NIDCD) filter
NIH Clinical Center (CC) (1) Apply NIH Clinical Center (CC) filter
NIH Office of Behavior and Social Science Research (OBSSR) (1) Apply NIH Office of Behavior and Social Science Research (OBSSR) filter
Active Projects (7) Apply Active Projects filter
Completed Projects (6) Apply Completed Projects filter
Foundation for the National Institutes of Health
11400 Rockville Pike, Suite 600
Email: foundation@fnih.org
For 17 years, Charity Navigator has rated the FNIH as an organization that "exceeds or meets industry standards."
© 1996-2020 Foundation for the National Institutes of Health, Inc. All Rights Reserved.